We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

No 'Silver Bullet' for COVID-19, Widespread Vaccine Distribution Unlikely To Occur For Some Time, Says WHO

By HospiMedica International staff writers
Posted on 10 Aug 2020
World Health Organization
World Health Organization
The World Health Organization (WHO Geneva, Switzerland) has warned that although a number of COVID-19 vaccines are now in Phase 3 clinical trials, no silver bullet presently exists and there may never be one.

In his opening remarks at the media briefing on COVID-19 on August 3, Tedros Adhanom Ghebreyesus, the WHO Director-General told reporters that serology studies indicated that most people remained susceptible to the coronavirus, even in areas that have experienced severe outbreaks. While progress was being made in identifying treatments that can help people with the most serious forms of COVID-19 recover, there was a need for countries to engage in the Access to COVID-19 Tools (ACT) Accelerator, participate in relevant clinical trials, and prepare for safe and effective therapeutics and vaccine introduction.

Given that several COVID-19 vaccines are now in Phase 3 clinical trials, Ghebreyesus said that the WHO was hopeful of a number of effective vaccines becoming available that can help prevent people from infection. However, he warned that there was no silver bullet at the moment and there might never be, and widespread vaccine distribution was unlikely to occur for some time.

Speaking on the WHO’s continued efforts to study the origins of the virus that causes COVID-19, Ghebreyesus informed that the WHO advance team that had travelled to China had concluded their mission to lay the groundwork for further joint efforts to identify the virus origins. As a result of these efforts, WHO and Chinese experts had drafted the Terms of Reference for the studies and program of work for an international team, led by WHO that would include leading scientists and researchers from China as well as around the world. Epidemiological studies were set to begin in Wuhan in order to identify the potential source of infection of the early cases, according to Ghebreyesus, and the evidence and hypotheses generated through the work would lay the ground for further, longer-term studies.

Related Links:

World Health Organization

Gold Member
CPAP Ventilator
Somnus DM18
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Emergency Ventilator
Shangrila935
Endoscopy Display
E190

Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more